essence study semaglutide (#wegovy/#ozempic) has better results, thus far, in its phase 3 fatty liver trial than its previous phase 2 trial it seems. 72-week data presented at The Liver Meeting 2024: American Association Semaglutide 2·4 mg once weekly
Description
Food and Drug Administration has approved semaglutide (Wegovy) injection for chronic weight management in adults with obesity or overweight with at least one weight-related condition
00068-7/asset/096c9be0-b6df-496c-ad71-95f35e424b2e/main.assets/gr2_lrg.jpg)
The outcome is fewer stalled intakes, clearer expectations, and a smoother baseline start
The Medicine Prize will be announced first
We further explore the potential actions of multi-agonist drugs as well as the mechanisms through which gut-brain communication can be used to achieve long-term weight loss without negative side effects
Consider diet and testing for optimal health
